Alzheimer's Disease: Recent Concepts on the Relation of Mitochondrial Disturbances, Excitotoxicity, Neuroinflammation, and Kynurenines

Journal of Alzheimer's Disease

Volumn 62, Issue 2, 2018, Pages 523-547

  Zádori, Dénes ^a   Veres, Gábor ^a   Szalárdy, Levente ^a   Klivényi, Péter ^a   Vécsei, László ^a,b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

3 hydroxy L kynurenine; Alzheimer's disease; glutamate excitotoxicity; kynurenic acid; kynurenine pathway; mitochondrial dysfunction; neuroinflammation; quinolinic acid; tryptophan metabolism

Indexed keywords

3 HYDROXYANTHRANILIC ACID; 3 HYDROXYKYNURENINE; GLUTAMIC ACID; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENIC ACID; KYNURENINE; QUINOLINIC ACID; TRYPTOPHAN; GLUTAMATE RECEPTOR; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EXCITOTOXICITY; EXPERIMENTAL MODEL; HUMAN; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TRYPTOPHAN METABOLISM; ANIMAL; CENTRAL NERVOUS SYSTEM; DISEASE MODEL; ENERGY METABOLISM; IMMUNOLOGY; INFLAMMATION; INNATE IMMUNITY; METABOLISM; MITOCHONDRION; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; ANIMALS; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; GLUTAMIC ACID; HUMANS; IMMUNITY, INNATE; INFLAMMATION; KYNURENINE; MITOCHONDRIA; QUINOLINIC ACID; REACTIVE OXYGEN SPECIES; RECEPTORS, GLUTAMATE; SIGNAL TRANSDUCTION;

EID: 85043577852     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-170929     Document Type: Review

References (318)

1. Robinson M, Lee BY, Hane FT (2017) Recent progress in Alzheimer's disease research, part 2: Genetics and epidemiology. J Alzheimers Dis 57, 317-330.
2. Hane FT, Lee BY, Leonenko Z (2017) Recent progress in Alzheimer's disease research, part 1: Pathology. J Alzheimers Dis 57, 1-28.
3. Hane FT, Robinson M, Lee BY, Bai O, Leonenko Z, Albert MS (2017) Recent progress in Alzheimer's disease research, part 3: Diagnosis and treatment. J Alzheimers Dis 57, 645-665.
4. Tse KH, Herrup K (2017) Re-imagining Alzheimer's disease \-The diminishing importance of amyloid and a glimpse of what lies ahead. J Neurochem 143, 432-444.
5. Vecsei L, Szalardy L, Fulop F, Toldi J (2013) Kynurenines in the CNS: Recent advances and new questions. Nat Rev Drug Discov 12, 64-82.
6. Cabezas-Opazo FA, Vergara-Pulgar K, Perez MJ, Jara C, Osorio-Fuentealba C, Quintanilla RA (2015) Mitochondrial dysfunction contributes to the pathogenesis of Alzheimer's disease. Oxid Med Cell Longev 2015, 509654.
7. Adiele RC, Adiele CA (2016) Mitochondrial regulatory pathways in the pathogenesis of Alzheimer's disease. J Alzheimers Dis 53, 1257-1270.
8. Cai Q, Tammineni P (2017) Mitochondrial aspects of synaptic dysfunction in Alzheimer's disease. J Alzheimers Dis 57, 1087-1103.
9. ChanDC(2006) Mitochondrial fusion and fission in mammals. Annu Rev Cell Dev Biol 22, 79-99.
10. Cagalinec M, Safiulina D, Liiv M, Liiv J, Choubey V, Wareski P, Veksler V, Kaasik A (2013) Principles of the mitochondrial fusion and fission cycle in neurons. J Cell Sci 126, 2187-2197.
11. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, KressY,VintersHV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PL, Jones PK, Petersen RB, Perry G, Smith MA (2001) Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21, 3017-3023.
12. Wang X, Su B, Siedlak SL, Moreira PI, Fujioka H,WangY, Casadesus G, Zhu X (2008) Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci U S A 105, 19318-19323.
13. Wang X, Su B, Lee HG, Li X, Perry G, Smith MA, Zhu X (2009) Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J Neurosci 29, 9090-9103.
14. Park J, Choi H, Min JS, Kim B, Lee SR, Yun JW, Choi MS, Chang KT, Lee DS (2015) Loss of mitofusin 2 links beta-amyloid-mediated mitochondrial fragmentation and Cdk5-induced oxidative stress in neuron cells. J Neurochem 132, 687-702.
15. Calkins MJ, Manczak M, Mao P, Shirendeb U, Reddy PH (2011) Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. Hum Mol Genet 20, 4515-4529.
16. Wang Z,Wang B, Yang L, Guo Q, Aithmitti N, Songyang Z, Zheng H (2009) Presynaptic and postsynaptic interaction of the amyloid precursor protein promotes peripheral and central synaptogenesis. J Neurosci 29, 10788-10801.
17. Wang X, Perry G, SmithMA,ZhuX(2010) Amyloid-betaderived diffusible ligands cause impaired axonal transport of mitochondria in neurons. Neurodegener Dis 7, 56-59.
18. Du H, Guo L, Yan S, Sosunov AA, McKhann GM, Yan SS (2010) Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc Natl Acad Sci U S A 107, 18670-18675.
19. Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH (2006) Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: Implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 15, 1437-1449.
20. Devi L, Prabhu BM, Galati DF, Avadhani NG, Anandatheerthavarada HK (2006) Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J Neurosci 26, 9057-9068.
21. Hansson Petersen CA, Alikhani N, Behbahani H, Wiehager B, Pavlov PF, Alafuzoff I, Leinonen V, Ito A, Winblad B, Glaser E, Ankarcrona M (2008) The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci U S A 105, 13145-13150.
22. Dragicevic N, Mamcarz M, Zhu Y, Buzzeo R, Tan J, Arendash GW, Bradshaw PC (2010) Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice. J Alzheimers Dis 20(Suppl 2), S535-550.
23. Manczak M, Calkins MJ, ReddyPH(2011) Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: Implications for neuronal damage. Hum Mol Genet 20, 2495-2509.
24. DuBoff B, Gotz J, Feany MB (2012) Tau promotes neurodegeneration via DRP1 mislocalization 'in vivo. Neuron 75, 618-632.
25. Schulz KL, Eckert A, Rhein V, Mai S, Haase W, Reichert AS, Jendrach M, Muller WE, Leuner K (2012) A new link to mitochondrial impairment in tauopathies. Mol Neurobiol 46, 205-216.
26. Manczak M, Reddy PH (2012) Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer's disease neurons: Implications for mitochondrial dysfunction and neuronal damage. Hum Mol Genet 21, 2538-2547.
27. RheinV, Song X,Wiesner A, Ittner LM, Baysang G, Meier F, Ozmen L, Bluethmann H, Drose S, Brandt U, Savaskan E, Czech C, Gotz J, Eckert A (2009) Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci U S A 106, 20057-20062.
28. Yao J, Du H, Yan S, Fang F, Wang C, Lue LF, Guo L, Chen D, Stern DM, Gunn Moore FJ, Xi Chen J, Arancio O, Yan SS (2011) Inhibition of amyloid-beta (Abeta) peptidebinding alcohol dehydrogenase-Abeta interaction reduces Abeta accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease. J Neurosci 31, 2313-2320.
29. Parker WD Jr, Filley CM, Parks JK (1990) Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 40, 1302-1303.
30. Mutisya EM, Bowling AC, Beal MF (1994) Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J Neurochem 63, 2179-2184.
31. Schagger H, Ohm TG (1995) Human diseases with defects in oxidative phosphorylation. 2. F1F0 ATP-synthase defects in Alzheimer disease revealed by blue native polyacrylamide gel electrophoresis. Eur J Biochem 227, 916-921.
32. Maurer I, Zierz S, Moller HJ (2000) A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol Aging 21, 455-462.
33. Manczak M, Park BS, Jung Y, Reddy PH (2004) Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: Implications for early mitochondrial dysfunction and oxidative damage. Neuromolecular Med 5, 147-162.
34. Sorbi S, Bird ED, Blass JP (1983) Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. Ann Neurol 13, 72-78.
35. Sheu KF, Kim YT, Blass JP, Weksler ME (1985) An immunochemical study of the pyruvate dehydrogenase deficit in Alzheimer's disease brain. Ann Neurol 17, 444-449.
36. Mastrogiacomo F, Bergeron C, Kish SJ (1993) Brain alpha-ketoglutarate dehydrogenase complex activity in Alzheimer's disease. J Neurochem 61, 2007-2014.
37. Richards JG, Higgins GA, Ouagazzal AM, Ozmen L, Kew JN, Bohrmann B, Malherbe P, Brockhaus M, Loetscher H, Czech C, Huber G, Bluethmann H, Jacobsen H, Kemp JA (2003) PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J Neurosci 23, 8989-9003.
38. Keil U, Bonert A, Marques CA, Scherping I, Weyermann J, Strosznajder JB, Muller-Spahn F, Haass C, Czech C, Pradier L, Muller WE, Eckert A (2004) Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J Biol Chem 279, 50310-50320.
39. Crouch PJ, Blake R, Duce JA, Ciccotosto GD, Li QX, Barnham KJ, Curtain CC, Cherny RA, Cappai R, Dyrks T, Masters CL, Trounce IA (2005) Copperdependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J Neurosci 25, 672-679.
40. Gillardon F, RistW, Kussmaul L, Vogel J, BergM, Danzer K, Kraut N, Hengerer B (2007) Proteomic and functional alterations in brain mitochondria from Tg2576 mice occur before amyloid plaque deposition. Proteomics 7, 605-616.
41. Eckert A, Hauptmann S, Scherping I, Meinhardt J, Rhein V, Drose S, Brandt U, Fandrich M, Muller WE, Gotz J (2008) Oligomeric and fibrillar species of betaamyloid (A beta 42) both impair mitochondrial function in P301L tau transgenic mice. J Mol Med (Berl) 86, 1255-1267.
42. Hauptmann S, Scherping I, Drose S, Brandt U, Schulz KL, Jendrach M, Leuner K, Eckert A, Muller WE (2009) Mitochondrial dysfunction: An early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging 30, 1574-1586.
43. Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, BrintonRD(2009) Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad SciUS A 106, 14670-14675.
44. Hyun DH, Mughal MR, Yang H, Lee JH, Ko EJ, Hunt ND, de Cabo R, Mattson MP (2010) The plasma membrane redox system is impaired by amyloid beta-peptide and in the hippocampus and cerebral cortex of 3xTgAD mice. Exp Neurol 225, 423-429.
45. Leuner K, SchuttT,Kurz C, Eckert SH, Schiller C, Occhipinti A, Mai S, Jendrach M, Eckert GP, Kruse SE, Palmiter RD, Brandt U, Drose S, Wittig I, Willem M, Haass C, Reichert AS, Muller WE (2012) Mitochondrion-derived reactive oxygen species lead to enhanced amyloid beta formation. Antioxid Redox Signal 16, 1421-1433.
46. Stockburger C, Gold VA, Pallas T, Kolesova N, Miano D, Leuner K, Muller WE (2014) A cell model for the initial phase of sporadic Alzheimer's disease. J Alzheimers Dis 42, 395-411.
47. Grimm A, Biliouris EE, Lang UE, Gotz J, Mensah-Nyagan AG, Eckert A (2016) Sex hormone-related neurosteroids differentially rescue bioenergetic deficits induced by amyloid-beta or hyperphosphorylated tau protein. Cell Mol Life Sci 73, 201-215.
48. Mecocci P, MacGarvey U, BealMF(1994) Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 36, 747-751.
49. Lin MT, Simon DK, Ahn CH, Kim LM, Beal MF (2002) High aggregate burden of somatic mtDNApoint mutations in aging and Alzheimer's disease brain. Hum Mol Genet 11, 133-145.
50. WeiW,Keogh MJ,Wilson I, Coxhead J, Ryan S, Rollinson S, Griffin H, Kurzawa-Akanbi M, Santibanez-Koref M, Talbot K, Turner MR, McKenzie CA, Troakes C, Attems J, Smith C, Al Sarraj S, Morris CM, Ansorge O, Pickering-Brown S, Ironside JW, Chinnery PF (2017) Mitochondrial DNA point mutations and relative copy number in 1363 disease and control human brains. Acta Neuropathol Commun 5, 13.
51. WeiW,Keogh MJ,Wilson I, Coxhead J, Ryan S, Rollinson S, Griffin H, Kurzawa-Akanbi M, Santibanez-Koref M, Talbot K, Turner MR, McKenzie CA, Troakes C, Attems J, Smith C, Al Sarraj S, Morris CM, Ansorge O, Pickering-Brown S, Ironside JW, Chinnery PF (2017) Erratum to: Mitochondrial DNA point mutations and relative copy number in 1363 disease and control human brains. Acta Neuropathol Commun 5, 17.
52. Yamaguchi H,Yamazaki T, Ishiguro K, Shoji M, Nakazato Y, Hirai S (1992) Ultrastructural localization of Alzheimer amyloid beta/A4 protein precursor in the cytoplasm of neurons and senile plaque-associated astrocytes. Acta Neuropathol 85, 15-22.
53. Parks JK, Smith TS, Trimmer PA, Bennett JP Jr, Parker WD Jr (2001) Neurotoxic Abeta peptides increase oxidative stress in vivo through NMDA-receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro. J Neurochem 76, 1050-1056.
54. Casley CS, Canevari L, Land JM, Clark JB, Sharpe MA (2002) Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J Neurochem 80, 91-100.
55. Casley CS, Land JM, Sharpe MA, Clark JB, Duchen MR, Canevari L (2002) Beta-amyloid fragment 25-35 causes mitochondrial dysfunction in primary cortical neurons. Neurobiol Dis 10, 258-267.
56. Aleardi AM, Benard G, Augereau O, Malgat M, Talbot JC, Mazat JP, Letellier T, Dachary-Prigent J, Solaini GC, Rossignol R (2005) Gradual alteration of mitochondrial structure and function by beta-amyloids: Importance of membrane viscosity changes, energy deprivation, reactive oxygen species production, and cytochrome c release. J Bioenerg Biomembr 37, 207-225.
57. Lustbader JW, Cirilli M, Lin C, XuHW, Takuma K,Wang N, Caspersen C, Chen X, Pollak S, Chaney M, Trinchese F, Liu S, Gunn-Moore F, Lue LF,Walker DG, Kuppusamy P, Zewier ZL, Arancio O, Stern D, Yan SS, Wu H (2004) ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304, 448-452.
58. Du H, Guo L, Fang F, Chen D, Sosunov AA, McKhann GM, Yan Y, Wang C, Zhang H, Molkentin JD, Gunn-Moore FJ, Vonsattel JP, Arancio O, Chen JX, Yan SD (2008) Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat Med 14, 1097-1105.
59. Manczak M, Reddy PH (2012) Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease. Hum Mol Genet 21, 5131-5146.
60. Mattson MP, Partin J, Begley JG (1998) Amyloid betapeptide induces apoptosis-related events in synapses and dendrites. Brain Res 807, 167-176.
61. Mungarro-Menchaca X, Ferrera P, Moran J, Arias C (2002) beta-Amyloid peptide induces ultrastructural changes in synaptosomes and potentiates mitochondrial dysfunction in the presence of ryanodine. J Neurosci Res 68, 89-96.
62. D'AmelioM,CavallucciV, Middei S, Marchetti C, Pacioni S, Ferri A, Diamantini A, De Zio D, Carrara P, Battistini L, Moreno S, Bacci A, Ammassari-Teule M, Marie H, Cecconi F (2011) Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. Nat Neurosci 14, 69-76.
63. Bartley MG, Marquardt K, Kirchhof D, Wilkins HM, Patterson D, Linseman DA (2012) Overexpression of amyloid-beta protein precursor induces mitochondrial oxidative stress and activates the intrinsic apoptotic cascade. J Alzheimers Dis 28, 855-868.
64. Gabuzda D, Busciglio J, Chen LB, Matsudaira P, Yankner BA (1994) Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem 269, 13623-13628.
65. Tamagno E, Parola M, Bardini P, Piccini A, Borghi R, Guglielmotto M, Santoro G, Davit A, Danni O, Smith MA, Perry G,TabatonM(2005) Beta-siteAPPcleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J Neurochem 92, 628-636.
66. Tamagno E, Guglielmotto M, Aragno M, Borghi R, Autelli R, Giliberto L, Muraca G, Danni O, Zhu X, Smith MA, Perry G, Jo DG, Mattson MP, TabatonM(2008) Oxidative stress activates a positive feedback between the gammaand beta-secretase cleavages of the beta-amyloid precursor protein. J Neurochem 104, 683-695.
67. Guglielmotto M, Aragno M, Autelli R, Giliberto L, Novo E, Colombatto S, Danni O, Parola M, Smith MA, Perry G, Tamagno E, Tabaton M (2009) The up-regulation of BACE1 mediated by hypoxia and ischemic injury: Role of oxidative stress and HIF1alpha. J Neurochem 108, 1045-1056.
68. Dumont M, Stack C, Elipenahli C, Jainuddin S, Gerges M, Starkova NN, Yang L, Starkov AA, Beal F (2011) Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice. FASEB J 25, 4063-4072.
69. David DC, Hauptmann S, Scherping I, Schuessel K, Keil U, Rizzu P, Ravid R, Drose S, Brandt U, MullerWE,Eckert A, Gotz J (2005) Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J Biol Chem 280, 23802-23814.
70. Bu G (2009) Apolipoprotein E and its receptors in Alzheimer's disease: Pathways, pathogenesis and therapy. Nat Rev Neurosci 10, 333-344.
71. Holtzman DM, Herz J, Bu G (2012) Apolipoprotein E and apolipoprotein E receptors: Normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med 2, a006312.
72. Liu CC, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol 9, 106-118.
73. Grimm A, Friedland K, Eckert A (2016) Mitochondrial dysfunction: The missing link between aging and sporadic Alzheimer's disease. Biogerontology 17, 281-296.
74. Gibson GE, Haroutunian V, Zhang H, Park LC, Shi Q, Lesser M, Mohs RC, Sheu RK, Blass JP (2000) Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype. Ann Neurol 48, 297-303.
75. Chen HK, Ji ZS, Dodson SE, Miranda RD, Rosenblum CI, Reynolds IJ, Freedman SB, Weisgraber KH, Huang Y, Mahley RW(2011) Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease. J Biol Chem 286, 5215-5221.
76. Nakamura T,Watanabe A, Fujino T, Hosono T, Michikawa M (2009) Apolipoprotein E4 (1-272) fragment is associated with mitochondrial proteins and affects mitochondrial function in neuronal cells. Mol Neurodegener 4, 35.
77. Hollenbeck PJ, Saxton WM (2005) The axonal transport of mitochondria. J Cell Sci 118, 5411-5419.
78. Sheng ZH (2014) Mitochondrial trafficking and anchoring in neurons: New insight and implications. J Cell Biol 204, 1087-1098.
79. Dai J, Buijs RM, Kamphorst W, Swaab DF (2002) Impaired axonal transport of cortical neurons in Alzheimer's disease is associated with neuropathological changes. Brain Res 948, 138-144.
80. Pigino G, Morfini G, Pelsman A, Mattson MP, Brady ST, Busciglio J (2003) Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport. J Neurosci 23, 4499-4508.
81. Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, Raman R, Davies P, Masliah E,Williams DS, Goldstein LS (2005) Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 307, 1282-1288.
82. RuiY, Tiwari P, Xie Z, Zheng JQ (2006) Acute impairment of mitochondrial trafficking by beta-amyloid peptides in hippocampal neurons. J Neurosci 26, 10480-10487.
83. Lazarov O, Morfini GA, Pigino G, Gadadhar A, Chen X, Robinson J, Ho H, Brady ST, Sisodia SS (2007) Impairments in fast axonal transport and motor neuron deficits in transgenic mice expressing familial Alzheimer's disease-linked mutant presenilin 1. J Neurosci 27, 7011-7020.
84. Vossel KA, Zhang K, Brodbeck J, Daub AC, Sharma P, Finkbeiner S, Cui B, Mucke L (2010) Tau reduction prevents Abeta-induced defects in axonal transport. Science 330, 198.
85. Calkins MJ, Reddy PH (2011) Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer's disease neurons. Biochim Biophys Acta 1812, 507-513.
86. Reddy PH (2011) Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's disease. Brain Res 1415, 136-148.
87. Reddy PH, Tripathi R, Troung Q, Tirumala K, Reddy TP, Anekonda V, Shirendeb UP, Calkins MJ, Reddy AP, Mao P, Manczak M (2012) Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: Implications to mitochondria-targeted antioxidant therapeutics. Biochim Biophys Acta 1822, 639-649.
88. Deng Y, Xiong Z, Chen P, Wei J, Chen S, Yan Z (2014) Beta-amyloid impairs the regulation of N-methyl-D-aspartate receptors by glycogen synthase kinase 3. Neurobiol Aging 35, 449-459.
89. Vossel KA, Xu JC, Fomenko V, Miyamoto T, Suberbielle E, Knox JA, Ho K, Kim DH, Yu GQ, Mucke L (2015) Tau reduction prevents Abeta-induced axonal transport deficits by blocking activation of GSK3beta. J Cell Biol 209, 419-433.
90. Qin W, Haroutunian V, Katsel P, Cardozo CP, Ho L, Buxbaum JD, Pasinetti GM (2009) PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. Arch Neurol 66, 352-361.
91. Sheng B, Wang X, Su B, Lee HG, Casadesus G, Perry G, Zhu X (2012) Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease. J Neurochem 120, 419-429.
92. Abramov E, Dolev I, Fogel H, Ciccotosto GD, Ruff E, Slutsky I (2009) Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses. Nat Neurosci 12, 1567-1576.
93. Puzzo D, Privitera L, Fa M, Staniszewski A, Hashimoto G, Aziz F, Sakurai M, Ribe EM, Troy CM, Mercken M, Jung SS, Palmeri A, Arancio O (2011) Endogenous amyloidbeta is necessary for hippocampal synaptic plasticity and memory. Ann Neurol 69, 819-830.
94. Parameshwaran K, Dhanasekaran M, Suppiramaniam V (2008) Amyloid beta peptides and glutamatergic synaptic dysregulation. Exp Neurol 210, 7-13.
95. Tovar KR, Westbrook GL (1999) The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro. J Neurosci 19, 4180-4188.
96. Hardingham GE, Fukunaga Y, Bading H (2002) Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 5, 405-414.
97. Ivanov A, Pellegrino C, Rama S, Dumalska I, Salyha Y, Ben-Ari Y, Medina I (2006) Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal-regulated kinases (ERK) activity in cultured rat hippocampal neurons. J Physiol 572, 789-798.
98. Goebel-Goody SM, Davies KD, Alvestad Linger RM, Freund RK, Browning MD (2009) Phospho-regulation of synaptic and extrasynaptic N-methyl-d-aspartate receptors in adult hippocampal slices. Neuroscience 158, 1446-1459.
99. Huang Y, Shen W, Su J, Cheng B, Li D, Liu G, Zhou WX,ZhangYX(2017) Modulating the balance of synaptic and extrasynaptic NMDA receptors shows positive effects against amyloid-beta-induced neurotoxicity. J Alzheimers Dis 57, 885-897.
100. Zhou Q, Sheng M (2013) NMDA receptors in nervous system diseases. Neuropharmacology 74, 69-75.
101. Kim JH, Anwyl R, Suh YH, Djamgoz MB, Rowan MJ (2001) Use-dependent effects of amyloidogenic fragments of (beta)-amyloid precursor protein on synaptic plasticity in rat hippocampus in vivo. J Neurosci 21, 1327-1333.
102. Baudry M, Lynch G (2001) Remembrance of arguments past: How well is the glutamate receptor hypothesis of LTP holding up after 20 years? Neurobiol Learn Mem 76, 284-297.
103. Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA, Trommer BL (2002) Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 924, 133-140.
104. Escobar ML, DerrickB(2007) Long-term potentiation and depression as putative mechanisms for memory formation. In Neural Plasticity and Memory: From Genes to Brain Imaging, Bermúdez-Rattoni F, ed. CRC Press, Boca Raton (FL), pp. 15-45.
105. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P (2005) Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8, 1051-1058.
106. Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R (2006) AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 52, 831-843.
107. Ferreira IL, Bajouco LM, Mota SI, Auberson YP, Oliveira CR, Rego AC (2012) Amyloid beta peptide 1-42 disturbs intracellular calcium homeostasis through activation of GluN2B-containing N-methyl-d-aspartate receptors in cortical cultures. Cell Calcium 51, 95-106.
108. Sattler R, Xiong Z, Lu WY, Hafner M, MacDonald JF, TymianskiM(1999) Specific coupling ofNMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science 284, 1845-1848.
109. Liu Y, Wong TP, Aarts M, Rooyakkers A, Liu L, Lai TW, Wu DC, Lu J, Tymianski M, Craig AM, Wang YT (2007) NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci 27, 2846-2857.
110. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT,Wood M,Viola KL, KleinWL(2007) Abeta oligomerinduced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 27, 796-807.
111. Bordji K, Becerril-Ortega J, Nicole O, Buisson A (2010) Activation of extrasynaptic, but not synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and increases amyloid-ss production. J Neurosci 30, 15927-15942.
112. Danysz W, Parsons CG (2012) Alzheimer's disease, beta-amyloid, glutamate, NMDA receptors and memantine-searching for the connections. Br J Pharmacol 167, 324-352.
113. Amadoro G, Ciotti MT, Costanzi M, Cestari V, Calissano P, Canu N (2006) NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation. Proc Natl Acad Sci U S A 103, 2892-2897.
114. Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu GQ, Palop JJ, Noebels JL, Mucke L (2011) Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci 31, 700-711.
115. Ittner LM, Gotz J (2011) Amyloid-beta and tau-A toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 12, 65-72.
116. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE (1992) Beta-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 12, 376-389.
117. Parpura-Gill A, Beitz D, Uemura E (1997) The inhibitory effects of beta-amyloid on glutamate and glucose uptakes by cultured astrocytes. Brain Res 754, 65-71.
118. Fernandez-Tome P, Brera B, Arevalo MA, de Ceballos ML (2004) Beta-amyloid25-35 inhibits glutamate uptake in cultured neurons and astrocytes: Modulation of uptake as a survival mechanism. Neurobiol Dis 15, 580-589.
119. Matos M, Augusto E, Oliveira CR, Agostinho P (2008) Amyloid-beta peptide decreases glutamate uptake in cultured astrocytes: Involvement of oxidative stress and mitogen-activated protein kinase cascades. Neuroscience 156, 898-910.
120. Scimemi A, Meabon JS, Woltjer RL, Sullivan JM, Diamond JS, Cook DG (2013) Amyloid-beta1-42 slows clearance of synaptically released glutamate by mislocalizing astrocytic GLT-1. J Neurosci 33, 5312-5318.
121. Talantova M, Sanz-Blasco S, Zhang X, Xia P, Akhtar MW, Okamoto S, Dziewczapolski G, Nakamura T, Cao G, Pratt AE, Kang YJ, Tu S, Molokanova E, McKercher SR, Hires SA, Sason H, Stouffer DG, Buczynski MW, Solomon JP, Michael S, Powers ET, Kelly JW, Roberts A, Tong G, Fang-Newmeyer T, Parker J, Holland EA, Zhang D, Nakanishi N, Chen HS, Wolosker H, Wang Y, Parsons LH, Ambasudhan R, Masliah E, Heinemann SF, Pina-Crespo JC, Lipton SA (2013) Abeta induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci U S A 110, E2518-2527.
122. Schallier A, Smolders I, Van Dam D, Loyens E, De Deyn PP, Michotte A, Michotte Y, Massie A (2011) Region-and age-specific changes in glutamate transport in the AbetaPP23 mouse model for Alzheimer's disease. J Alzheimers Dis 24, 287-300.
123. Zumkehr J, Rodriguez-Ortiz CJ, Cheng D, Kieu Z,Wai T, Hawkins C, Kilian J, Lim SL, Medeiros R, Kitazawa M (2015) Ceftriaxone ameliorates tau pathology and cognitive decline via restoration of glial glutamate transporter in a mouse model of Alzheimer's disease. Neurobiol Aging 36, 2260-2271.
124. Li S, Mallory M, Alford M, Tanaka S, Masliah E (1997) Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J Neuropathol Exp Neurol 56, 901-911.
125. Beckstrom H, Julsrud L, Haugeto O, Dewar D, Graham DI, Lehre KP, Storm-Mathisen J, Danbolt NC (1999) Interindividual differences in the levels of the glutamate transportersGLASTandGLT, but no clear correlation with Alzheimer's disease. J Neurosci Res 55, 218-229.
126. Scott HA, Gebhardt FM, Mitrovic AD, Vandenberg RJ, Dodd PR (2011) Glutamate transporter variants reduce glutamate uptake in Alzheimer's disease. Neurobiol Aging 32, 553.e1-11.
127. Lewerenz J, Maher P (2015) Chronic glutamate toxicity in neurodegenerative diseases-What is the evidence? Front Neurosci 9, 469.
128. Qin S, Colin C, Hinners I, Gervais A, Cheret C, Mallat M (2006) System Xc-and apolipoprotein E expressed by microglia have opposite effects on the neurotoxicity of amyloid-beta peptide 1-40. J Neurosci 26, 3345-3356.
129. Novelli A, Reilly JA, Lysko PG, Henneberry RC (1988) Glutamate becomes neurotoxic via the N-methyl-Daspartate receptor when intracellular energy levels are reduced. Brain Res 451, 205-212.
130. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock DT, Kummer MP (2015) Neuroinflammation in Alzheimer's disease. Lancet Neurol 14, 388-405.
131. Heppner FL, Ransohoff RM, Becher B (2015) Immune attack: The role of inflammation in Alzheimer disease. Nat Rev Neurosci 16, 358-372.
132. Raj T, Rothamel K, Mostafavi S, Ye C, Lee MN, Replogle JM, Feng T, Lee M, Asinovski N, Frohlich I, Imboywa S, Von Korff A, Okada Y, Patsopoulos NA, Davis S, McCabe C, Paik HI, Srivastava GP, Raychaudhuri S, Hafler DA, Koller D, Regev A, Hacohen N, Mathis D, Benoist C, Stranger BE, De Jager PL (2014) Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science 344, 519-523.
133. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A (2011) Physiology of microglia. Physiol Rev 91, 461-553.
134. Ji K, Akgul G, Wollmuth LP, Tsirka SE (2013) Microglia actively regulate the number of functional synapses. PLoS One 8, e56293.
135. Parkhurst CN, Yang G, Ninan I, Savas JN, Yates JR, 3rd, Lafaille JJ, Hempstead BL, Littman DR, Gan WB (2013) Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell 155, 1596-1609.
136. Perlmutter LS, Scott SA, Barron E, Chui HC (1992) MHC class II-positive microglia in human brain: Association with Alzheimer lesions. J Neurosci Res 33, 549-558.
137. Yasuno F, Kosaka J, Ota M, Higuchi M, Ito H, Fujimura Y, Nozaki S, Takahashi S, Mizukami K, Asada T, Suhara T (2012) Increased binding of peripheral benzodiazepine receptor in mild cognitive impairmentdementia converters measured by positron emission tomography with (1)(1)C DAA1106. Psychiatry Res 203, 67-74.
138. Schuitemaker A, Kropholler MA, Boellaard R, van der Flier WM, Kloet RW, van der Doef TF, Knol DL, Windhorst AD, Luurtsema G, Barkhof F, Jonker C, Lammertsma AA, Scheltens P, van Berckel BN (2013) Microglial activation in Alzheimer's disease: An (R)-(1)(1)C PK11195 positron emission tomography study. Neurobiol Aging 34, 128-136.
139. Akama KT, Van Eldik LJ (2000) Beta-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1beta-and tumor necrosis factoralpha (TNFalpha)-dependent, and involves a TNFalpha receptor-associated factor-and NFkappaB-inducing kinase-dependent signaling mechanism. J Biol Chem 275, 7918-7924.
140. Lue LF, Rydel R, Brigham EF, Yang LB, Hampel H, Murphy GM Jr, Brachova L, Yan SD, Walker DG, Shen Y, Rogers J (2001) Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia 35, 72-79.
141. Walker DG, Link J, Lue LF, Dalsing-Hernandez JE, Boyes BE (2006) Gene expression changes by amyloid beta peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory processes. J Leukoc Biol 79, 596-610.
142. Lee CY, Landreth GE (2010) The role of microglia in amyloid clearance from the AD brain. J Neural Transm (Vienna) 117, 949-960.
143. Prokop S, Miller KR, Heppner FL (2013) Microglia actions in Alzheimer's disease. Acta Neuropathol 126, 461-477.
144. Hickman SE, Allison EK, El Khoury J (2008) Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci 28, 8354-8360.
145. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fievet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanche H, Dartigues JF, Tzourio C, Gut I,Van Broeckhoven C, Alperovitch A, Lathrop M, Amouyel P (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41, 1094-1099.
146. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Beaumont H,Warden D,Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy ER, Hardy J, Mead S, Fox NC, Rossor M, Collinge J, Maier W, Jessen F, Ruther E, Schurmann B, Heun R, Kolsch H, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Gallacher J, Hull M, Rujescu D, Giegling I, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Pankratz VS, Sando SB, Aasly JO, Barcikowska M, Wszolek ZK, Dickson DW, Graff-Radford NR, Petersen RC, van Duijn CM, Breteler MM, Ikram MA, DeStefano AL, Fitzpatrick AL, Lopez O, Launer LJ, Seshadri S, Berr C, Campion D, Epelbaum J, Dartigues JF, Tzourio C, Alperovitch A, Lathrop M, Feulner TM, Friedrich P, Riehle C, Krawczak M, Schreiber S, Mayhaus M, Nicolhaus S, Wagenpfeil S, Steinberg S, Stefansson H, Stefansson K, Snaedal J, Bjornsson S, Jonsson PV, Chouraki V, Genier-Boley B, Hiltunen M, Soininen H, Combarros O, Zelenika D, Delepine M, Bullido MJ, Pasquier F, Mateo I, Frank-Garcia A, Porcellini E, Hanon O, Coto E, Alvarez V, Bosco P, Siciliano G, Mancuso M, Panza F, Solfrizzi V, Nacmias B, Sorbi S, Bossu P, Piccardi P, Arosio B, Annoni G, Seripa D, Pilotto A, Scarpini E, Galimberti D, Brice A, Hannequin D, Licastro F, Jones L, Holmans PA, Jonsson T, Riemenschneider M, Morgan K, Younkin SG, Owen MJ, O'Donovan M, Amouyel P, Williams J (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 43, 429-435.
147. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, Cruchaga C, Kauwe JS, Nowotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT, Green RC, Rogaeva E, St George-Hyslop P, Arnold SE, Barber R, Beach T, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Carlson CS, Carney RM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cotman CW, Cummings JL, DeCarli C, DeKosky ST, Diaz-Arrastia R, Dick M, Dickson DW, Ellis WG, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Giordani B, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin LW, Johnson N, Karlawish J, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Lah JJ, Levey AI, Lieberman AP, Lopez OL, Mack WJ, Marson DC, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Parisi JE, Perl DP, Peskind E, Petersen RC, Poon WW, Quinn JF, Rajbhandary RA, Raskind M, Reisberg B, Ringman JM, Roberson ED, Rosenberg RN, Sano M, Schneider LS, Seeley W, Shelanski ML, Slifer MA, Smith CD, Sonnen JA, Spina S, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Woltjer RL, Cantwell LB, Dombroski BA, Beekly D, Lunetta KL, Martin ER, Kamboh MI, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Montine TJ, Goate AM, Blacker D, TsuangDW, Hakonarson H,Kukull WA, Foroud TM, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD (2011) Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 43, 436-441.
148. Krabbe G, Halle A, Matyash V, Rinnenthal JL, Eom GD, Bernhardt U, Miller KR, Prokop S, Kettenmann H, Heppner FL (2013) Functional impairment of microglia coincides with beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS One 8, e60921.
149. Guerreiro R, Hardy J (2013) TREM2 and neurodegenerative disease. N Engl J Med 369, 1569-1570.
150. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, van Duijn CM, Thorsteinsdottir U, Kong A, Stefansson K (2013) Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 368, 107-116.
151. Bradshaw EM, Chibnik LB, Keenan BT, Ottoboni L, Raj T, Tang A, Rosenkrantz LL, Imboywa S, Lee M, Von Korff A, Morris MC, Evans DA, Johnson K, Sperling RA, Schneider JA, Bennett DA, De Jager PL (2013) CD33 Alzheimer's disease locus: Altered monocyte function and amyloid biology. Nat Neurosci 16, 848-850.
152. Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, Hooli B, Choi SH, Hyman BT, Tanzi RE (2013) Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 78, 631-643.
153. Thambisetty M, An Y, Nalls M, Sojkova J, Swaminathan S, Zhou Y, Singleton AB, Wong DF, Ferrucci L, Saykin AJ, Resnick SM (2013) Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype. Biol Psychiatry 73, 422-428.
154. Lucin KM, O'Brien CE, Bieri G, Czirr E, Mosher KI, Abbey RJ, Mastroeni DF, Rogers J, Spencer B, Masliah E, Wyss-Coray T (2013) Microglial beclin 1 regulates retromer trafficking and phagocytosis and is impaired in Alzheimer's disease. Neuron 79, 873-886.
155. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, O'Banion K, Klockgether T, Van Leuven F, Landreth GE (2005) Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128, 1442-1453.
156. HenekaMT,Reyes-Irisarri E, Hull M,KummerMP(2011) Impact and therapeutic potential of PPARs in Alzheimer's disease. Curr Neuropharmacol 9, 643-650.
157. Yamanaka M, Ishikawa T, Griep A, Axt D, Kummer MP, HenekaMT(2012) PPARgamma/RXRalpha-induced and CD36-mediated microglial amyloid-beta phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J Neurosci 32, 17321-17331.
158. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE (2012) ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335, 1503-1506.
159. Szalardy L, Zadori D, Tanczos E, Simu M, Bencsik K, Vecsei L, Klivenyi P (2013) Elevated levels of PPARgamma in the cerebrospinal fluid of patients with multiple sclerosis. Neurosci Lett 554, 131-134.
160. Szalardy L, Zadori D, Bencsik K, Vecsei L, Klivenyi P (2017) Unlike PPARgamma, neither other PPARs nor PGC-1alpha is elevated in the cerebrospinal fluid of patients with multiple sclerosis. Neurosci Lett 651, 128-133.
161. Mandybur TI, Chuirazzi CC (1990) Astrocytes and the plaques of Alzheimer's disease. Neurology 40, 635-639.
162. Akiyama H,Tooyama I,KawamataT, Ikeda K, McGeerPL (1993) Morphological diversities of CD44 positive astrocytes in the cerebral cortex of normal subjects and patients with Alzheimer's disease. Brain Res 632, 249-259.
163. Kato S, Gondo T, HoshiiY, Takahashi M,Yamada M, Ishihara T (1998) Confocal observation of senile plaques in Alzheimer's disease: Senile plaque morphology and relationship between senile plaques and astrocytes. Pathol Int 48, 332-340.
164. Pihlaja R, Koistinaho J, Kauppinen R, Sandholm J, Tanila H, Koistinaho M (2011) Multiple cellular and molecular mechanisms are involved in human Abeta clearance by transplanted adult astrocytes. Glia 59, 1643-1657.
165. Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F, Silverstein SC, Husemann J (2003) Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med 9, 453-457.
166. Nagele RG, D'Andrea MR, Lee H,VenkataramanV,Wang HY (2003) Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res 971, 197-209.
167. KoistinahoM,Lin S,Wu X, EstermanM,Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR, Paul SM (2004) Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med 10, 719-726.
168. Terwel D, Steffensen KR, Verghese PB, Kummer MP, Gustafsson JA, Holtzman DM, HenekaMT(2011) Critical role of astroglial apolipoprotein E and liver X receptoralpha expression for microglial Abeta phagocytosis. J Neurosci 31, 7049-7059.
169. Furman JL, Sama DM, Gant JC, Beckett TL, Murphy MP, Bachstetter AD, Van Eldik LJ, Norris CM (2012) Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease. J Neurosci 32, 16129-16140.
170. Griffin WS, Stanley LC, Ling C, White L, MacLeodV, Perrot LJ, White CL 3rd, Araoz C (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 86, 7611-7615.
171. Cacabelos R, Alvarez XA, Fernandez-Novoa L, Franco A, Mangues R, Pellicer A, Nishimura T (1994) Brain interleukin-1 beta in Alzheimer's disease and vascular dementia. Methods Find Exp Clin Pharmacol 16, 141-151.
172. Hull M, Berger M, Volk B, Bauer J (1996) Occurrence of interleukin-6 in cortical plaques of Alzheimer's disease patients may precede transformation of diffuse into neuritic plaques. Ann N Y Acad Sci 777, 205-212.
173. Mehlhorn G, Hollborn M, Schliebs R (2000) Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. Int J Dev Neurosci 18, 423-431.
174. Abbas N, Bednar I, Mix E, Marie S, Paterson D, Ljungberg A, Morris C, Winblad B, Nordberg A, Zhu J (2002) Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice. J Neuroimmunol 126, 50-57.
175. Hampel H, Haslinger A, Scheloske M, Padberg F, Fischer P, Unger J, Teipel SJ, Neumann M, Rosenberg C, Oshida R, Hulette C, Pongratz D, Ewers M, Kretzschmar HA, Moller HJ (2005) Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain. Eur Arch Psychiatry Clin Neurosci 255, 269-278.
176. Patel NS, Paris D, Mathura V, Quadros AN, Crawford FC, Mullan MJ (2005) Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease. J Neuroinflammation 2, 9.
177. Schwab C, Klegeris A, McGeer PL (2010) Inflammation in transgenic mouse models of neurodegenerative disorders. Biochim Biophys Acta 1802, 889-902.
178. Morimoto K, Horio J, Satoh H, Sue L, Beach T, Arita S, Tooyama I, Konishi Y (2011) Expression profiles of cytokines in the brains of Alzheimer's disease (AD) patients compared to the brains of non-demented patients with and without increasing AD pathology. J Alzheimers Dis 25, 59-76.
179. Vom Berg J, Prokop S, Miller KR, Obst J, Kalin RE, Lopategui-Cabezas I, Wegner A, Mair F, Schipke CG, Peters O, Winter Y, Becher B, Heppner FL (2012) Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat Med 18, 1812-1819.
180. Sudduth TL, Schmitt FA, Nelson PT,Wilcock DM (2013) Neuroinflammatory phenotype in early Alzheimer's disease. Neurobiol Aging 34, 1051-1059.
181. Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A, Axt D, Remus A, Tzeng TC, Gelpi E, Halle A, Korte M, Latz E, Golenbock DT (2013) NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493, 674-678.
182. Brosseron F, Krauthausen M, Kummer M, Heneka MT (2014) Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: A comparative overview. Mol Neurobiol 50, 534-544.
183. Tarkowski E, Andreasen N, Tarkowski A, Blennow K (2003) Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry 74, 1200-1205.
184. Buchhave P, Zetterberg H, Blennow K, Minthon L, Janciauskiene S, Hansson O (2010) Soluble TNF receptors are associated with Abeta metabolism and conversion to dementia in subjects with mild cognitive impairment. Neurobiol Aging 31, 1877-1884.
185. Szalardy L, Zadori D, Klivenyi P, Vecsei L (2016) The role of cerebrospinal fluid biomarkers in the evolution of diagnostic criteria in Alzheimer's disease: Shortcomings in prodromal diagnosis. J Alzheimers Dis 53, 373-392.
186. Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J, Duman RS, Flavell RA (2008) Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med 14, 681-687.
187. Chakrabarty P, Jansen-West K, Beccard A, Ceballos-Diaz C, Levites Y, Verbeeck C, Zubair AC, Dickson D, Golde TE, Das P (2010) Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: Evidence against inflammation as a driving force for amyloid deposition. FASEB J 24, 548-559.
188. Chakrabarty P, Herring A, Ceballos-Diaz C, Das P, Golde TE (2011) Hippocampal expression of murine TNFalpha results in attenuation of amyloid deposition in vivo. Mol Neurodegener 6, 16.
189. Chakrabarty P, Tianbai L, Herring A, Ceballos-Diaz C, Das P, Golde TE (2012) Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition. Mol Neurodegener 7, 36.
190. Chakrabarty P, Li A, Ceballos-Diaz C, Eddy JA, Funk CC, Moore B, DiNunno N, Rosario AM, Cruz PE, Verbeeck C, Sacino A, Nix S, Janus C, Price ND, Das P, Golde TE (2015) IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron 85, 519-533.
191. Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR,Yuen E, Assaid C, Nessly ML, Norman BA, Baranak CC, Reines SA(2005)Arandomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 30, 1204-1215.
192. Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M (2008) Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): Results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 65, 896-905.
193. Leoutsakos JM, Muthen BO, Breitner JC, Lyketsos CG (2012) Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of preclinical Alzheimer disease: Findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial. Int J Geriatr Psychiatry 27, 364-374.
194. Jaturapatporn D, Isaac MG, McCleery J, Tabet N (2012) Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst Rev, CD006378.
195. ADAPT-FS RG (2015) Follow-up evaluation of cognitive function in the randomized Alzheimer's Disease Antiinflammatory Prevention Trial and its Follow-up Study. Alzheimers Dement 11, 216-225.
196. Montine TJ, Sidell KR, Crews BC, Markesbery WR,Marnett LJ, Roberts LJ 2nd, Morrow JD (1999) Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology 53, 1495-1498.
197. Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, Biere AL, Citron M, Landreth G (2003) Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 23, 7504-7509.
198. Shie FS, Breyer RM, Montine TJ (2005) Microglia lacking E Prostanoid Receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta-activated neurotoxicity. Am J Pathol 166, 1163-1172.
199. Combrinck M, Williams J, De Berardinis MA, Warden D, Puopolo M, Smith AD, Minghetti L (2006) Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease. J Neurol Neurosurg Psychiatry 77, 85-88.
200. Johansson JU, Woodling NS, Wang Q, Panchal M, Liang X, Trueba-Saiz A, Brown HD, Mhatre SD, Loui T, Andreasson KI (2015) Prostaglandin signaling suppresses beneficial microglial function in Alzheimer's disease models. J Clin Invest 125, 350-364.
201. Wolf H (1974) The effect of hormones and vitamin B6 on urinary excretion of metabolites of the kynurenine pathway. Scand J Clin Lab Invest Suppl 136, 1-186.
202. Zadori D, Klivenyi P, Plangar I, Toldi J, Vecsei L (2011) Endogenous neuroprotection in chronic neurodegenerative disorders: With particular regard to the kynurenines. J Cell Mol Med 15, 701-717.
203. Gonzalez EsquivelD, Ramirez-Ortega D, Pineda B, Castro N, Rios C, Perez de la Cruz V (2017) Kynurenine pathway metabolites and enzymes involved in redox reactions. Neuropharmacology 112, 331-345.
204. Klivenyi P, Toldi J, Vecsei L (2004) Kynurenines in neurodegenerative disorders: Therapeutic consideration. Adv Exp Med Biol 541, 169-183.
205. Zadori D, Klivenyi P, Vamos E, Fulop F, Toldi J, Vecsei L (2009) Kynurenines in chronic neurodegenerative disorders: Future therapeutic strategies. J Neural Transm (Vienna) 116, 1403-1409.
206. Kincses ZT, Toldi J, Vecsei L (2010) Kynurenines, neurodegeneration and Alzheimer's disease. J Cell Mol Med 14, 2045-2054.
207. Plangar I, Zadori D, Klivenyi P, Toldi J, Vecsei L (2011) Targeting the kynurenine pathway-related alterations in Alzheimer's disease: A future therapeutic strategy. J Alzheimers Dis 24(Suppl 2), 199-209.
208. Stone TW (1993) Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45, 309-379.
209. Fulop F, Szatmari I, Vamos E, Zadori D, Toldi J, Vecsei L (2009) Syntheses, transformations and pharmaceutical applications of kynurenic acid derivatives. Curr Med Chem 16, 4828-4842.
210. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ (2012) Kynurenines in the mammalian brain: When physiology meets pathology. Nat Rev Neurosci 13, 465-477.
211. Zadori D,Veres G, Szalardy L, Klivenyi P, Fulop F, Toldi J, Vecsei L (2016) Inhibitors of the kynurenine pathway as neurotherapeutics: A patent review (2012-2015). Expert Opin Ther Pat 26, 815-832.
212. Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, Fuchs D (1999) Degradation of tryptophan in neurodegenerative disorders. Adv Exp Med Biol 467, 133-138.
213. Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, Fuchs D (2000) Tryptophan degradation and immune activation in Alzheimer's disease. J Neural Transm (Vienna) 107, 343-353.
214. Guillemin GJ, Brew BJ, Noonan CE, Takikawa O, Cullen KM (2005) Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol Appl Neurobiol 31, 395-404.
215. WuW, Nicolazzo JA,Wen L, Chung R, Stankovic R, Bao SS, Lim CK, Brew BJ, Cullen KM, Guillemin GJ (2013) Expression of tryptophan 2,3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer's disease brain. PLoS One 8, 9.
216. Bonda DJ, Mailankot M, Stone JG, Garrett MR, Staniszewska M, Castellani RJ, Siedlak SL, Zhu X, Lee HG, Perry G, Nagaraj RH, SmithMA(2010) Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease. Redox Rep 15, 161-168.
217. Guillemin GJ, Smythe GA, Veas LA, Takikawa O, Brew BJ (2003) A beta 1-42 induces production of quinolinic acid by human macrophages and microglia. Neuroreport 14, 2311-2315.
218. Dykens JA, Sullivan SG, SternA(1987) Oxidative reactivity of the tryptophan metabolites 3-hydroxyanthranilate, cinnabarinate, quinolinate and picolinate. Biochem Pharmacol 36, 211-217.
219. Jhamandas K, Boegman RJ, Beninger RJ, BialikM(1990) Quinolinate-induced cortical cholinergic damage: Modulation by tryptophan metabolites. Brain Res 529, 185-191.
220. Eastman CL, GuilarteTR(1990) The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine. Neurochem Res 15, 1101-1107.
221. Okuda S, Nishiyama N, Saito H, Katsuki H (1998) 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J Neurochem 70, 299-307.
222. Colin-Gonzalez AL, Maldonado PD, SantamariaA(2013) 3-Hydroxykynurenine: An intriguing molecule exerting dual actions in the central nervous system. Neurotoxicology 34, 189-204.
223. Colin-Gonzalez AL, Maya-Lopez M, Pedraza-Chaverri J, Ali SF, Chavarria A, Santamaria A (2014) The Janus faces of 3-hydroxykynurenine: Dual redox modulatory activity and lack of neurotoxicity in the rat striatum. Brain Res 1589, 1-14.
224. Notarangelo FM, Wu HQ, Macherone A, Graham DR, Schwarcz R (2012) Gas chromatography/tandem mass spectrometry detection of extracellular kynurenine and related metabolites in normal and lesioned rat brain. Anal Biochem 421, 573-581.
225. Reyes-Ocampo J, Ramirez-Ortega D, Cervantes GI, Pineda B, Balderas PM, Gonzalez-Esquivel D, Sanchez-Chapul L, Lugo-Huitron R, Silva-Adaya D, Rios C, Jimenez-Anguiano A, Perez-de la Cruz V (2015) Mitochondrial dysfunction related to cell damage induced by 3-hydroxykynurenine and 3-hydroxyanthranilic acid: Non-dependent-effect of early reactive oxygen species production. Neurotoxicology 50, 81-91.
226. Heyes MP, Achim CL, Wiley CA, Major EO, Saito K, Markey SP (1996) Human microglia convert L-tryptophan into the neurotoxin quinolinic acid. Biochem J 320, 595-597.
227. Espey MG, Chernyshev ON, Reinhard JF Jr, Namboodiri MA, Colton CA (1997) Activated human microglia produce the excitotoxin quinolinic acid. Neuroreport 8, 431-434.
228. Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ, Croitoru J, Brew BJ (2001) Kynurenine pathway metabolism in human astrocytes: A paradox for neuronal protection. J Neurochem 78, 842-853.
229. Guillemin GJ, Smythe G, Takikawa O, Brew BJ (2005) Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 49, 15-23.
230. Pearson SJ, Reynolds GP (1992) Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease. Neurosci Lett 144, 199-201.
231. Baran H, Jellinger K, Deecke L (1999) Kynurenine metabolism in Alzheimer's disease. J Neural Transm (Vienna) 106, 165-181.
232. Schwarz MJ, Guillemin GJ, Teipel SJ, Buerger K, Hampel H (2013) Increased 3-hydroxykynurenine serum concentrations differentiate Alzheimer's disease patients from controls. Eur Arch Psychiatry Clin Neurosci 263, 345-352.
233. Duleu S, Mangas A, Sevin F,Veyret B, Bessede A, Geffard M (2010) Circulating antibodies to IDO/THO pathway metabolites in Alzheimer's disease. Int J Alzheimers Dis 2010, 501541.
234. Gulaj E, Pawlak K, Bien B, Pawlak D (2010) Kynurenine and its metabolites in Alzheimer's disease patients. Adv Med Sci 55, 204-211.
235. Tohgi H, Abe T, Takahashi S, Kimura M, Takahashi J, Kikuchi T (1992) Concentrations of serotonin and its related substances in the cerebrospinal fluid in patients with Alzheimer type dementia. Neurosci Lett 141, 9-12.
236. Browne TC, McQuillan K, McManus RM, O'Reilly JA, Mills KH, Lynch MA (2013) IFN-gamma production by amyloid beta-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease. J Immunol 190, 2241-2251.
237. Scolding NJ, Joseph F, Kirby PA,Mazanti I, Gray F, Mikol J, Ellison D, Hilton DA, Williams TL, MacKenzie JM, Xuereb JH, Love S (2005) Abeta-related angiitis: Primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Brain 128, 500-515.
238. de Carvalho LP, Bochet P, Rossier J (1996) The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits. Neurochem Int 28, 445-452.
239. Stone TW, Perkins MN (1981) Quinolinic acid: A potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol 72, 411-412.
240. Connick JH, Stone TW (1988) Quinolinic acid effects on amino acid release from the rat cerebral cortex in vitro and in vivo. Br J Pharmacol 93, 868-876.
241. Tavares RG, Tasca CI, Santos CE, Alves LB, Porciuncula LO, Emanuelli T, Souza DO (2002) Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem Int 40, 621-627.
242. Rahman A, Ting K, Cullen KM, Braidy N, Brew BJ, Guillemin GJ (2009) The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS One 4, e6344.
243. Rios C, Santamaria A (1991) Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem Res 16, 1139-1143.
244. Behan WM, McDonald M, Darlington LG, Stone TW (1999) Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: Protection by melatonin and deprenyl. Br J Pharmacol 128, 1754-1760.
245. Montine TJ, Neely MD, Quinn JF, Beal MF, Markesbery WR, Roberts LJ, Morrow JD (2002) Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic Biol Med 33, 620-626.
246. St'astny F, Lisy V, Mares V, Lisa V, Balcar VJ, Santamaria A (2004) Quinolinic acid induces NMDA receptormediated lipid peroxidation in rat brain microvessels. Redox Rep 9, 229-233.
247. Stipek S, Stastny F, Platenik J, Crkovska J, Zima T (1997) The effect of quinolinate on rat brain lipid peroxidation is dependent on iron. Neurochem Int 30, 233-237.
248. Rodriguez-Martinez E, Camacho A, Maldonado PD, Pedraza-Chaverri J, Santamaria D, Galvan-Arzate S, Santamaria A (2000) Effect of quinolinic acid on endogenous antioxidants in rat corpus striatum. Brain Res 858, 436-439.
249. Ganzella M, Jardim FM, Boeck CR, Vendite D (2006) Time course of oxidative events in the hippocampus following intracerebroventricular infusion of quinolinic acid in mice. Neurosci Res 55, 397-402.
250. Braidy N, Grant R, Adams S, Guillemin GJ (2010) Neuroprotective effects of naturally occurring polyphenols on quinolinic acid-induced excitotoxicity in human neurons. FEBS J 277, 368-382.
251. Perez-De La Cruz V, Elinos-Calderon D, Carrillo-Mora P, Silva-Adaya D, Konigsberg M, Moran J, Ali SF, Chanez-Cardenas ME, Perez-De La Cruz G, Santamaria A (2010) Time-course correlation of early toxic events in three models of striatal damage: Modulation by proteases inhibition. Neurochem Int 56, 834-842.
252. Lugo-Huitron R, Ugalde Muniz P, Pineda B, Pedraza-Chaverri J, Rios C, Perez-de la Cruz V (2013) Quinolinic acid: An endogenous neurotoxin with multiple targets. Oxid Med Cell Longev 2013, 104024.
253. Moroni F, Lombardi G, Robitaille Y, Etienne P (1986) Senile dementia and Alzheimer's disease: Lack of changes of the cortical content of quinolinic acid. Neurobiol Aging 7, 249-253.
254. Sofic E, Halket J, Przyborowska A, Riederer P, Beckmann H, Sandler M, Jellinger K (1989) Brain quinolinic acid in Alzheimer's dementia. Eur Arch Psychiatry Neurol Sci 239, 177-179.
255. Mourdian MM, Heyes MP, Pan JB, Heuser IJ, Markey SP, Chase TN, MouradianMM(1989) No changes in central quinolinic acid levels in Alzheimer's disease. Neurosci Lett 105, 233-238.
256. Guillemin GJ, Brew BJ, Noonan CE, Knight TG, Smythe GA, Cullen KM (2007) Mass spectrometric detection of quinolinic acid in microdissected Alzheimer's disease plaques. Int Congr Ser 1304, 404-408.
257. Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M, Dilling LA, Elia J, Kruesi MJ, Lackner A, et al. (1992) Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 115, 1249-1273.
258. Terness P, Bauer TM, Rose L, Dufter C,Watzlik A, Simon H, OpelzG(2002) Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: Mediation of suppression by tryptophan metabolites. J Exp Med 196, 447-457.
259. Fallarino F, Grohmann U,Vacca C, Bianchi R, Orabona C, Spreca A, Fioretti MC, Puccetti P (2002) T cell apoptosis by tryptophan catabolism. Cell Death Differ 9, 1069-1077.
260. Bauer TM, Jiga LP, Chuang JJ, Randazzo M, Opelz G, Terness P (2005) Studying the immunosuppressive role of indoleamine 2,3-dioxygenase: Tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo. Transpl Int 18, 95-100.
261. Guillemin GJ, Croitoru-Lamoury J, Dormont D, Armati PJ, Brew BJ (2003) Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes. Glia 41, 371-381.
262. Guillemin GJ, Wang L, Brew BJ (2005) Quinolinic acid selectively induces apoptosis of human astrocytes: Potential role in AIDS dementia complex. J Neuroinflammation 2, 16.
263. Ting KK, Brew BJ, Guillemin GJ (2009) Effect of quinolinic acid on human astrocytes morphology and functions: Implications in Alzheimer's disease. J Neuroinflammation 6, 36.
264. Wu HQ, Lee SC, Schwarcz R (2000) Systemic administration of 4-chlorokynurenine prevents quinolinate neurotoxicity in the rat hippocampus. Eur J Pharmacol 390, 267-274.
265. Parli CJ, Krieter P, Schmidt B (1980) Metabolism of 6-chlorotryptophan to 4-chloro-3-hydroxyanthranilic acid: A potent inhibitor of 3-hydroxyanthranilic acid oxidase. Arch Biochem Biophys 203, 161-166.
266. Guidetti P,Wu HQ, Schwarcz R (2000) In situ produced 7-chlorokynurenate provides protection against quinolinateand malonate-induced neurotoxicity in the rat striatum. Exp Neurol 163, 123-130.
267. Zadori D, Klivenyi P, Szalardy L, Fulop F, Toldi J, Vecsei L (2012) Mitochondrial disturbances, excitotoxicity, neuroinflammation and kynurenines: Novel therapeutic strategies for neurodegenerative disorders. J Neurol Sci 322, 187-191.
268. Heredi J, Berko AM, Jankovics F, Iwamori T, Iwamori N, Ono E, Horvath S, Kis Z, Toldi J, Vecsei L, Gellert L (2017) Astrocytic and neuronal localization of kynurenine aminotransferase-2 in the adult mouse brain. Brain Struct Funct 222, 1663-1672.
269. Perkins MN, Stone TW (1982) An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res 247, 184-187.
270. Kessler M, Terramani T, Lynch G, Baudry M (1989) A glycine site associated with N-methyl-D-aspartic acid receptors: Characterization and identification of a new class of antagonists. J Neurochem 52, 1319-1328.
271. Swartz KJ, During MJ, Freese A, BealMF(1990) Cerebral synthesis and release of kynurenic acid: An endogenous antagonist of excitatory amino acid receptors. J Neurosci 10, 2965-2973.
272. Linderholm K, Powell S, Olsson E, Holtze M, Snodgrass R, Erhardt S (2010) Role of the NMDA-receptor in prepulse inhibition in the rat. Int J Tryptophan Res 3, 1-12.
273. Prescott C, Weeks AM, Staley KJ, Partin KM (2006) Kynurenic acid has a dual action on AMPA receptor responses. Neurosci Lett 402, 108-112.
274. Rozsa E, Robotka H, Vecsei L, Toldi J (2008) The Janusface kynurenic acid. J Neural Transm (Vienna) 115, 1087-1091.
275. Goda K, HamaneY, Kishimoto R, OgishiY(1999) Radical scavenging properties of tryptophan metabolites. Estimation of their radical reactivity. Adv Exp Med Biol 467, 397-402.
276. Hardeland R, Zsizsik BK, Poeggeler B, Fuhrberg B, Holst S, Coto-Montes A (1999) Indole-3-pyruvic and-propionic acids, kynurenic acid, and related metabolites as luminophores and free-radical scavengers. Adv Exp Med Biol 467, 389-395.
277. Lugo-Huitron R, Blanco-Ayala T, Ugalde-Muniz P, Carrillo-Mora P, Pedraza-Chaverri J, Silva-Adaya D, Maldonado PD, Torres I, Pinzon E, Ortiz-Islas E, Lopez T, Garcia E, Pineda B, Torres-Ramos M, Santamaria A, La CruzVP(2011) On the antioxidant properties of kynurenic acid: Free radical scavenging activity and inhibition of oxidative stress. Neurotoxicol Teratol 33, 538-547.
278. Fukuda A, Muramatsu K, Okabe A, Shimano Y, Hida H, Fujimoto I, Nishino H (1998) NMDA receptor-mediated differential laminar susceptibility to the intracellular Ca2+ accumulation induced by oxygen-glucose deprivation in rat neocortical slices. J Neurophysiol 79, 430-438.
279. Csillik A, Knyihar E, Okuno E, Krisztin-Peva B, Csillik B, Vecsei L (2002) Effect of 3-nitropropionic acid on kynurenine aminotransferase in the rat brain. Exp Neurol 177, 233-241.
280. Luchowski P, Luchowska E, Turski WA, Urbanska EM (2002) 1-Methyl-4-phenylpyridinium and 3-nitropropionic acid diminish cortical synthesis of kynurenic acid via interference with kynurenine aminotransferases in rats. Neurosci Lett 330, 49-52.
281. Wang J, Simonavicius N, Wu X, Swaminath G, Reagan J, Tian H, Ling L (2006) Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem 281, 22021-22028.
282. Klein C, Patte-Mensah C, Taleb O, Bourguignon JJ, Schmitt M, Bihel F, Maitre M, Mensah-NyaganAG(2013) The neuroprotector kynurenic acid increases neuronal cell survival through neprilysin induction. Neuropharmacology 70, 254-260.
283. Park MH, Lee JK, Choi S, Ahn J, Jin HK, Park JS, Bae JS (2013) Recombinant soluble neprilysin reduces amyloid-beta accumulation and improves memory impairment in Alzheimer's disease mice. Brain Res 1529, 113-124.
284. Huttenrauch M, Baches S, Gerth J, Bayer TA, Weggen S, Wirths O (2015) Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer's disease. J Alzheimers Dis 44, 1291-1302.
285. Guillemin GJ, Williams KR, Smith DG, Smythe GA, Croitoru-Lamoury J, Brew BJ (2003) Quinolinic acid in the pathogenesis of Alzheimer's disease. Adv Exp Med Biol 527, 167-176.
286. Steiner L, Gold M, Mengel D, Dodel R, Bach JP (2014) The endogenous alpha7 nicotinic acetylcholine receptor antagonist kynurenic acid modulates amyloidbeta-induced inflammation in BV-2 microglial cells. J Neurol Sci 344, 94-99.
287. Maaetoft-Udsen K, Shimoda LM, Frokiaer H, Turner H (2012) Aryl hydrocarbon receptor ligand effects in RBL2H3 cells. J Immunotoxicol 9, 327-337.
288. DiNatale BC, Murray IA, Schroeder JC, Flaveny CA, Lahoti TS, Laurenzana EM, Omiecinski CJ, Perdew GH (2010) Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol Sci 115, 89-97.
289. Beal MF, Matson WR, Storey E, Milbury P, Ryan EA, Ogawa T, Bird ED (1992) Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex. J Neurol Sci 108, 80-87.
290. Francis PT, Sims NR, Procter AW, Bowen DM (1993) Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: Investigative and therapeutic perspectives. J Neurochem 60, 1589-1604.
291. Ulas J, Weihmuller FB, Brunner LC, Joyce JN, Marshall JF, Cotman CW (1994) Selective increase of NMDAsensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/ Alzheimer's disease patients: An autoradiographic study. J Neurosci 14, 6317-6324.
292. Knyihar-Csillik E, Okuno E, Vecsei L (1999) Effects of in vivo sodium azide administration on the immunohistochemical localization of kynurenine aminotransferase in the rat brain. Neuroscience 94, 269-277.
293. Hartai Z, Juhasz A, Rimanoczy A, Janaky T, Donko T, Dux L, Penke B, Toth GK, Janka Z, Kalman J (2007) Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease. Neurochem Int 50, 308-313.
294. Wennstrom M, Nielsen HM, Orhan F, Londos E, Minthon L, Erhardt S (2014) Kynurenic acid levels in cerebrospinal fluid from patients with Alzheimer's disease or dementia with Lewy bodies. Int J Tryptophan Res 7, 1-7.
295. Fitzjohn SM, Morton RA, Kuenzi F, Rosahl TW, Shearman M, Lewis H, Smith D, Reynolds DS, Davies CH, Collingridge GL, Seabrook GR (2001) Age-related impairment of synaptic transmission but normal long-term potentiation in transgenic mice that overexpress the human APP695SWE mutant form of amyloid precursor protein. J Neurosci 21, 4691-4698.
296. Carrillo-Mora P, Mendez-Cuesta LA, Perez-De La Cruz V, Fortoul-van Der Goes TI, Santamaria A (2010) Protective effect of systemic L-kynurenine and probenecid administration on behavioural and morphological alterations induced by toxic soluble amyloid beta (25-35) in rat hippocampus. Behav Brain Res 210, 240-250.
297. Robotka H, Nemeth H, Somlai C, Vecsei L, Toldi J (2005) Systemically administered glucosamine-kynurenic acid, but not pure kynurenic acid, is effective in decreasing the evoked activity in area CA1 of the rat hippocampus. Eur J Pharmacol 513, 75-80.
298. Deora GS, Kantham S, Chan S, Dighe SN, Veliyath SK, McColl G, Parat MO, McGeary RP, Ross BP (2017) Multifunctional analogs of kynurenic acid for the treatment of Alzheimer's disease: Synthesis, pharmacology, and molecular modeling studies. ACS Chem Neurosci 8, 2667-2675.
299. Li L, Sengupta A, Haque N, Grundke-Iqbal I, Iqbal K (2004) Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett 566, 261-269.
300. Vecsei L, Beal MF (1991) Comparative behavioral and pharmacological studies with centrally administered kynurenine and kynurenic acid in rats. Eur J Pharmacol 196, 239-246.
301. Shepard PD, Joy B, Clerkin L, Schwarcz R (2003) Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology 28, 1454-1462.
302. Erhardt S, Schwieler L, Emanuelsson C, Geyer M (2004) Endogenous kynurenic acid disrupts prepulse inhibition. Biol Psychiatry 56, 255-260.
303. Chess AC, Simoni MK, Alling TE, Bucci DJ (2007) Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull 33, 797-804.
304. Chess AC, Landers AM, Bucci DJ (2009) L-kynurenine treatment alters contextual fear conditioning and context discrimination but not cue-specific fear conditioning. Behav Brain Res 201, 325-331.
305. Potter MC, Elmer GI, Bergeron R, Albuquerque EX, Guidetti P, Wu HQ, Schwarcz R (2010) Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology 35, 1734-1742.
306. Pocivavsek A,Wu HQ, Potter MC, Elmer GI, Pellicciari R, Schwarcz R (2011) Fluctuations in endogenous kynurenic acid control hippocampal glutamate and memory. Neuropsychopharmacology 36, 2357-2367.
307. Mony L, Kew JN, Gunthorpe MJ, Paoletti P (2009) Allosteric modulators of NR2B-containing NMDA receptors: Molecular mechanisms and therapeutic potential. Br J Pharmacol 157, 1301-1317.
308. Szalardy L, Zadori D, Toldi J, Fulop F, Klivenyi P, Vecsei L (2012) Manipulating kynurenic acid levels in the brain-on the edge between neuroprotection and cognitive dysfunction. Curr Top Med Chem 12, 1797-1806.
309. Borza I, Kolok S, Galgoczy K, Gere A, Horvath C, Farkas S, Greiner I, Domany G (2007) Kynurenic acid amides as novelNR2BselectiveNMDAreceptor antagonists. Bioorg Med Chem Lett 17, 406-409.
310. Zadori D, Nyiri G, Szonyi A, Szatmari I, Fulop F, Toldi J, Freund TF, Vecsei L, Klivenyi P (2011) Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease. J Neural Transm (Vienna) 118, 865-875.
311. Gellert L, Fuzik J, Goblos A, Sarkozi K, Marosi M, Kis Z, Farkas T, Szatmari I, Fulop F, Vecsei L, Toldi J (2011) Neuroprotection with a new kynurenic acid analog in the four-vessel occlusion model of ischemia. Eur J Pharmacol 667, 182-187.
312. Nagy K, Plangar I, Tuka B, Gellert L, Varga D, Demeter I, Farkas T, Kis Z, Marosi M, Zadori D, Klivenyi P, Fulop F, Szatmari I, Vecsei L, Toldi J (2011) Synthesis and biological effects of some kynurenic acid analogs. Bioorg Med Chem 19, 7590-7596.
313. Gellert L, Varga D, Ruszka M, Toldi J, Farkas T, Szatmari I, Fulop F, Vecsei L, Kis Z (2012) Behavioural studies with a newly developed neuroprotective KYNA-amide. J Neural Transm (Vienna) 119, 165-172.
314. Varga D, Heredi J, Kanvasi Z, Ruszka M, Kis Z, Ono E, Iwamori N, Iwamori T, Takakuwa H, Vecsei L, Toldi J, Gellert L (2015) Systemic L-kynurenine sulfate administration disrupts object recognition memory, alters open field behavior and decreases c-Fos immunopositivity in C57Bl/6 mice. Front Behav Neurosci 9, 157.
315. Demeter I, Nagy K, Farkas T, Kis Z, Kocsis K, Knapp L, Gellert L, Fulop F,Vecsei L, Toldi J (2013) Paradox effects of kynurenines on LTP induction in the Wistar rat. An in vivo study. Neurosci Lett 553, 138-141.
316. Sas K, Robotka H, Toldi J, Vecsei L (2007) Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J Neurol Sci 257, 221-239.
317. Szalardy L, Klivenyi P, Zadori D, Fulop F, Toldi J, Vecsei L (2012) Mitochondrial disturbances, tryptophan metabolites and neurodegeneration: Medicinal chemistry aspects. Curr Med Chem 19, 1899-1920.
318. Zadori D, Veres G, Szalardy L, Klivenyi P, Toldi J, Vecsei L (2014) Glutamatergic dysfunctioning in Alzheimer's disease and related therapeutic targets. J Alzheimers Dis 42(Suppl 3), S177-187.